Company / PP&E (Net)
Axsome Therapeutics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$562.0K
FY2025
5-year range
$283.8K / $846.0K
FY2021-FY2025
Trend
-3.8%
vs FY2024
Sector context
#167 of 193
Health Care
What the data says
Axsome Therapeutics, Inc.'s pp&e (net) of $562,000 is lower than 87% of companies in the Health Care sector (FY2025). Declined from $846,000 to $562,000 over the past 2 years.
Based on SEC 10-K filings.
$562,000 in FY2025 with a 5-year CAGR of +60.6%.
Declined from $846,000 to $562,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -8.0%
- 5-Year CAGR
- +60.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 193This company $562.0K Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +60.6%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 3.8% year-over-year.
- Ranks #167 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $562.0K | -3.8% |
| FY2024 | $584.0K | -31.0% |
| FY2023 | $846.0K | +17.2% |
| FY2022 | $722.0K | +154.4% |
| FY2021 | $283.8K | +439.1% |
| FY2020 | $52.6K | +71.9% |
| FY2019 | $30.6K | -40.9% |
| FY2018 | $51.8K | -23.9% |
| FY2017 | $68.1K | -32.4% |
| FY2016 | $100.7K | +504.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026